{"id":87856,"date":"2026-05-15T09:20:25","date_gmt":"2026-05-15T03:50:25","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=87856"},"modified":"2026-05-15T09:20:27","modified_gmt":"2026-05-15T03:50:27","slug":"goldline-pharmaceutical-ipo-allotment-status-15-may-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/","title":{"rendered":"Goldline Pharmaceutical IPO Allotment Today 15 May 2026: Issue Subscribed 126.70x, Retail 178x, GMP at Rs 17-18, Listing 19 May"},"content":{"rendered":"<p><strong>The Goldline Pharmaceutical IPO allotment<\/strong> basis is being finalised today, 15 May 2026, after the issue received an extraordinary 126.70 times overall subscription on Day 3 data, with the retail individual investor category subscribed 178.06 times, NII at 167.37 times and QIB at 1.35 times. Allotted investors will have shares credited to demat accounts on Saturday, 17 May 2026, ahead of the BSE SME listing on Monday, 19 May 2026.<\/p><p>With retail subscribed 178 times, the Goldline Pharmaceutical IPO allotment will be by computerised lottery at 1 lot (6,000 shares) per successful applicant. At 178x retail subscription, approximately 1 in every 178 retail applicants will receive allotment. The grey market premium on 14 May stood at Rs 17 to Rs 18, implying an expected listing price of approximately Rs 60 to Rs 61 against the Rs 43 issue price, a 40 percent listing gain.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#Key_Data_Goldline_Pharmaceutical_IPO_Allotment_and_Listing_Timeline\" title=\"Key Data: Goldline Pharmaceutical IPO Allotment and Listing Timeline\">Key Data: Goldline Pharmaceutical IPO Allotment and Listing Timeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#How_to_Check_Goldline_Pharmaceutical_IPO_Allotment_Status_Today\" title=\"How to Check Goldline Pharmaceutical IPO Allotment Status Today\">How to Check Goldline Pharmaceutical IPO Allotment Status Today<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#Method_1_Bigshare_Services_Registrar_Website\" title=\"Method 1: Bigshare Services Registrar Website\">Method 1: Bigshare Services Registrar Website<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#Method_2_BSE_Website\" title=\"Method 2: BSE Website\">Method 2: BSE Website<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#Method_3_Broker_App_or_UPI_Platform\" title=\"Method 3: Broker App or UPI Platform\">Method 3: Broker App or UPI Platform<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#What_the_126x_Subscription_Means_for_Goldline_Pharmaceutical_IPO_Allotment\" title=\"What the 126x Subscription Means for Goldline Pharmaceutical IPO Allotment\">What the 126x Subscription Means for Goldline Pharmaceutical IPO Allotment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#Retail_Lottery_1_in_178_Applicants_Will_Receive_Shares\" title=\"Retail Lottery: 1 in 178 Applicants Will Receive Shares\">Retail Lottery: 1 in 178 Applicants Will Receive Shares<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#QIB_at_135x_Proportionate_Allotment\" title=\"QIB at 1.35x: Proportionate Allotment\">QIB at 1.35x: Proportionate Allotment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#NII_at_167x_Proportionate_Allotment_for_HNIs\" title=\"NII at 167x: Proportionate Allotment for HNIs\">NII at 167x: Proportionate Allotment for HNIs<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#Goldline_Pharmaceutical_IPO_Listing_Preview_GMP_at_Rs_17-18_Signals_40_Gain\" title=\"Goldline Pharmaceutical IPO Listing Preview: GMP at Rs 17-18 Signals 40% Gain\">Goldline Pharmaceutical IPO Listing Preview: GMP at Rs 17-18 Signals 40% Gain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#About_Goldline_Pharmaceutical_Why_It_Generated_126x_Demand\" title=\"About Goldline Pharmaceutical: Why It Generated 126x Demand\">About Goldline Pharmaceutical: Why It Generated 126x Demand<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#FAQs\" title=\"FAQs \">FAQs <\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#When_is_the_Goldline_Pharmaceutical_IPO_allotment_date\" title=\"When is the Goldline Pharmaceutical IPO allotment date?\">When is the Goldline Pharmaceutical IPO allotment date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#How_do_I_check_the_Goldline_Pharmaceutical_IPO_allotment_status\" title=\"How do I check the Goldline Pharmaceutical IPO allotment status?\">How do I check the Goldline Pharmaceutical IPO allotment status?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#What_was_the_final_Goldline_Pharmaceutical_IPO_subscription\" title=\"What was the final Goldline Pharmaceutical IPO subscription?\">What was the final Goldline Pharmaceutical IPO subscription?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#What_are_the_allotment_chances_in_Goldline_Pharmaceutical_IPO_for_retail_investors\" title=\"What are the allotment chances in Goldline Pharmaceutical IPO for retail investors?\">What are the allotment chances in Goldline Pharmaceutical IPO for retail investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/goldline-pharmaceutical-ipo-allotment-status-15-may-2026\/#What_is_the_expected_Goldline_Pharmaceutical_IPO_listing_price_on_19_May\" title=\"What is the expected Goldline Pharmaceutical IPO listing price on 19 May?\">What is the expected Goldline Pharmaceutical IPO listing price on 19 May?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Key_Data_Goldline_Pharmaceutical_IPO_Allotment_and_Listing_Timeline\"><\/span><strong>Key Data: Goldline Pharmaceutical IPO Allotment and Listing Timeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li><strong>Allotment Basis Finalisation: <\/strong>15 May 2026 (Today)<\/li>\n\n<li><strong>Credit of Shares to Demat: <\/strong>17 May 2026 (Saturday)<\/li>\n\n<li><strong>Refund Initiation: <\/strong>17 May 2026 (Saturday)<\/li>\n\n<li><strong>Listing on BSE SME: <\/strong>19 May 2026 (Monday)<\/li>\n\n<li><strong>Issue Price (Upper Band): <\/strong>Rs 43 per share<\/li>\n\n<li><strong>Price Band: <\/strong>Rs 41 to Rs 43<\/li>\n\n<li><strong>Issue Size: <\/strong>Rs 11.61 crore (27 lakh shares, 100% fresh issue)<\/li>\n\n<li><strong>Day 3 Overall Subscription: <\/strong>126.70 times<\/li>\n\n<li><strong>Retail Subscription (Day 3): <\/strong>178.06 times<\/li>\n\n<li><strong>NII Subscription (Day 3): <\/strong>167.37 times<\/li>\n\n<li><strong>QIB Subscription (Day 3): <\/strong>1.35 times<\/li>\n\n<li><strong>GMP (14 May 2026): <\/strong>Rs 17 to Rs 18 (40% implied listing premium)<\/li>\n\n<li><strong>Expected Listing Price (GMP basis): <\/strong>Approximately Rs 60 to Rs 61<\/li>\n\n<li><strong>Registrar: <\/strong>Bigshare Services Pvt Ltd<\/li>\n\n<li><strong>Market Maker: <\/strong>Nirman Share Brokers Pvt Ltd<\/li><\/ul><p>Track Goldline Pharmaceutical share price live post-allotment on the <a href=\"https:\/\/univest.in\/screeners\">Check the Univest Screener for live data<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_to_Check_Goldline_Pharmaceutical_IPO_Allotment_Status_Today\"><\/span><strong>How to Check Goldline Pharmaceutical IPO Allotment Status Today<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Method_1_Bigshare_Services_Registrar_Website\"><\/span><strong>Method 1: Bigshare Services Registrar Website<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Bigshare Services Pvt Ltd is the official registrar for the Goldline Pharmaceutical IPO. Visit the Bigshare registrar portal at ipo.bigshareonline.com, select Goldline Pharmaceutical IPO from the available list, enter your PAN number, application number or DP ID and client ID, and submit to view allotment status. Results will be published during the course of 15 May 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Method_2_BSE_Website\"><\/span><strong>Method 2: BSE Website<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Visit www.bseindia.com and navigate to the IPO allotment status section. Since the Goldline Pharmaceutical IPO is listed on BSE SME, the BSE website is the primary exchange source for verifying allotment. Enter your application credentials to confirm your Goldline Pharmaceutical IPO allotment status.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Method_3_Broker_App_or_UPI_Platform\"><\/span><strong>Method 3: Broker App or UPI Platform<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Most ASBA-enabled brokers including Zerodha, Upstox, Angel One, 5Paisa and Groww display IPO allotment results in the IPO section of their apps. The status will update once Bigshare Services publishes the basis of allotment during today&#8217;s session.<\/p><p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Tap to Access Best Research Pieces on Univest<\/strong><\/a><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_the_126x_Subscription_Means_for_Goldline_Pharmaceutical_IPO_Allotment\"><\/span><strong>What the 126x Subscription Means for Goldline Pharmaceutical IPO Allotment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Retail_Lottery_1_in_178_Applicants_Will_Receive_Shares\"><\/span><strong>Retail Lottery: 1 in 178 Applicants Will Receive Shares<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>With retail subscription at 178.06 times, the Goldline Pharmaceutical IPO allotment for retail investors is purely by computerised lottery. Each successful applicant receives exactly 1 lot (6,000 shares at Rs 43 = Rs 2,58,000 investment). Applying for more lots does not improve your chances. The lottery is drawn from the pool of unique retail applications at 1 lot per PAN.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"QIB_at_135x_Proportionate_Allotment\"><\/span><strong>QIB at 1.35x: Proportionate Allotment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The QIB category, which was allocated 50 percent of the Goldline Pharmaceutical IPO, subscribed only 1.35 times. QIB allotment is proportionate, meaning QIBs receive approximately 74 percent of their bid quantity. The low QIB subscription relative to the enormous retail demand of 178x is notable and should be tracked as a leading indicator for listing day institutional support.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"NII_at_167x_Proportionate_Allotment_for_HNIs\"><\/span><strong>NII at 167x: Proportionate Allotment for HNIs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>NII subscription at 167.37 times for the Goldline Pharmaceutical IPO allotment means HNIs receive approximately 0.60 percent of their bid quantity. A Rs 3,87,000 minimum HNI application (3 lots) would receive approximately Rs 23,200 worth of shares (6,000 shares at Rs 43 = Rs 2,58,000 value at issue price).<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Goldline_Pharmaceutical_IPO_Listing_Preview_GMP_at_Rs_17-18_Signals_40_Gain\"><\/span><strong>Goldline Pharmaceutical IPO Listing Preview: GMP at Rs 17-18 Signals 40% Gain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The grey market premium for Goldline Pharmaceutical on 14 May 2026 stood at Rs 17 to Rs 18, implying a listing price of Rs 60 to Rs 61 against the issue price of Rs 43. If the listing delivers on the GMP, allotted retail investors would earn approximately Rs 17,000 on a Rs 2,58,000 application, a 6.6 percent effective return on capital blocked.<\/p><p>The listing is on 19 May 2026 on BSE SME. The broader market conditions on that day will influence whether the actual listing price meets or exceeds the GMP target. With Nifty under pressure from crude oil above $107 and elevated VIX, SME listings can trade below GMP-implied levels even for well-subscribed issues. Monitor Nifty futures and broader market sentiment on Sunday night and Monday morning before the listing session.<\/p><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and insightful research pieces on Goldline Pharmaceutical live listing price and BSE SME tracking on 19 May!<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_Goldline_Pharmaceutical_Why_It_Generated_126x_Demand\"><\/span><strong>About Goldline Pharmaceutical: Why It Generated 126x Demand<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Goldline Pharmaceutical Limited is a Nagpur-based asset-light pharmaceutical marketing company, established in 2005, that markets branded pharma products across five therapeutic segments under the Goldline brand. With 15 third-party contract manufacturers, it sells through distributors across Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan and Bihar. FY25 revenue was Rs 28.06 crore (+19% year-on-year), PAT was Rs 2.83 crore (+56% year-on-year) and ROE stood at 27.34 percent. At 10.48x PE, the issue was priced below the pharma marketing industry average of 13 to 15 times, which attracted aggressive grey market and retail demand.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><strong>The Goldline Pharmaceutical IPO allotment<\/strong> is being finalised today on 15 May 2026 after the issue delivered exceptional 126.70 times overall subscription and 178 times retail demand. Check your Goldline Pharmaceutical IPO allotment status on the Bigshare Services registrar website or BSE portal using your PAN. Shares credit on 17 May and listing is on 19 May BSE SME. With GMP at Rs 17 to Rs 18 implying Rs 60 to Rs 61 listing price, allotted investors have a meaningful potential gain. Consult a SEBI-registered advisor before making hold or sell decisions on listing day.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_is_the_Goldline_Pharmaceutical_IPO_allotment_date\"><\/span><strong>When is the Goldline Pharmaceutical IPO allotment date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The Goldline Pharmaceutical IPO allotment basis is being finalised today, 15 May 2026. Shares will be credited to allottee demat accounts on 17 May 2026 and refunds for non-allottees will also be initiated on the same date. The BSE SME listing is on Monday, 19 May 2026.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_do_I_check_the_Goldline_Pharmaceutical_IPO_allotment_status\"><\/span><strong>How do I check the Goldline Pharmaceutical IPO allotment status?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>Check the Goldline Pharmaceutical IPO allotment status on the Bigshare Services registrar website (ipo.bigshareonline.com) using your PAN number, application number or DP ID. You can also check on the BSE website&#8217;s IPO allotment section or through your broker app from 15 May 2026 onwards.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_was_the_final_Goldline_Pharmaceutical_IPO_subscription\"><\/span><strong>What was the final Goldline Pharmaceutical IPO subscription?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>The Goldline Pharmaceutical IPO was subscribed 126.70 times overall on Day 3. Retail investors subscribed 178.06 times, NIIs subscribed 167.37 times and QIBs subscribed 1.35 times. The total bids received were for 24,93,54,000 shares against 19,68,000 shares on offer.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_are_the_allotment_chances_in_Goldline_Pharmaceutical_IPO_for_retail_investors\"><\/span><strong>What are the allotment chances in Goldline Pharmaceutical IPO for retail investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>With retail subscription at 178 times, approximately 1 in every 178 retail applicants will receive allotment in the Goldline Pharmaceutical IPO. The allotment is by computerised lottery at exactly 1 lot (6,000 shares) per successful applicant. Applying for more lots does not increase allotment probability.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_expected_Goldline_Pharmaceutical_IPO_listing_price_on_19_May\"><\/span><strong>What is the expected Goldline Pharmaceutical IPO listing price on 19 May?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p><strong>Ans. <\/strong>Based on the GMP of Rs 17 to Rs 18 as of 14 May 2026, the expected Goldline Pharmaceutical IPO listing price on BSE SME on 19 May is approximately Rs 60 to Rs 61, representing a potential gain of 40 percent over the Rs 43 issue price. GMP is unofficial and actual listing price may differ based on market conditions on 19 May.<\/p><p><\/p>","protected":false},"excerpt":{"rendered":"<p>The Goldline Pharmaceutical IPO allotment basis is being finalised today, 15 May 2026, after the issue received an extraordinary 126.70 times overall subscription on Day 3 data, with the retail individual investor category subscribed 178.06 times, NII at 167.37 times and QIB at 1.35 times. Allotted investors will have shares credited to demat accounts on<\/p>\n","protected":false},"author":35,"featured_media":87857,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3815],"class_list":["post-87856","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-ipo-allotment"],"metadata":{"_edit_lock":["1778817103:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["24"],"rank_math_seo_score":["79"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_title":["Goldline Pharmaceutical IPO Allotment Today 15 May 2026: 126x Subscribed, Check Now"],"rank_math_description":["Goldline Pharmaceutical IPO allotment today 15 May 2026. Final subscription 126.70x, retail 178x. GMP Rs 17-18. Check allotment on Bigshare Services. Listing 19 May BSE SME."],"rank_math_focus_keyword":["Goldline Pharmaceutical IPO"],"_thumbnail_id":["87857"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11514"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/15091954\/Goldline-Pharmaceutical.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=87856"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87856\/revisions"}],"predecessor-version":[{"id":87858,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/87856\/revisions\/87858"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/87857"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=87856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=87856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=87856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}